Oragenics

Oragenics

Company Details

WebsiteLinkedIn

Status: Public

Employees: 11-50

Location:

Tampa, Florida, United States

Type:

sample

Technology:

sample

sample

About: Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
BiopharmIQ
Oragenics | Active clinical trials on ClinicalTrials.gov

Active Clinical Trials Count | 0

No Active Trials Found On ClinicalTrials.gov.